SLC22A17 and chronic myelogenous leukemia, BCR-ABL1 positive: - SLC22A17 was stronger expressed in the untreated CML patients compared to normal PBMCs- SLC22A17 level was higher before treatment but decreased after FCR treatment- Blocking of SLC22A17 induced death in SLC22A17high CML cells but not in SLC22A17low/- CLL cells